GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass
- Conditions
- Sports Nutritional Sciences
- Interventions
- Dietary Supplement: D3 CreatineDietary Supplement: Creatine
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02519751
- Locations
- 🇬🇧
GSK Investigational Site, Brentford, United Kingdom
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02513654
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: FDC capsule of dutasteride and tamsulosin
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT02509104
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 222
- Registration Number
- NCT02504671
- Locations
- 🇬🇧
GSK Investigational Site, Leeds, United Kingdom
Bioequivalence Study for Mejoral 500 Product
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02504775
- Locations
- 🇲🇽
GSK Investigational Site, Mexico City, Mexico
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: Clop F1Drug: Clop F2Drug: Innovator
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02502812
- Locations
- 🇮🇳
GSK Investigational Site, Telangana, India
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT02502734
- Locations
- 🇩🇰
GSK Investigational Site, Randers, Denmark
A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT02497937
- Locations
- 🇺🇸
GSK Investigational Site, Rochester, Minnesota, United States
A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition
- Conditions
- Acne Vulgaris
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT02498288
- Locations
- 🇲🇽
GSK Investigational Site, Monterrey, Nuevo León, Mexico
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02496221
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States